Publication | Closed Access

Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18–70 years of age

VaccinologyVaccinationToll-like Receptor 9Agonist AdjuvantViral HepatitisImmunologyHepatitis BHepatitisVaccine TestingHumoral ImmunityVaccine EfficacyHealthy Adults 18–70Vaccine HesitancyMedicine